Table 3:

The effects of statin usage on progression of clinical and imaging metrics after adjustment for baseline serum LDL.

	Change from baseline (SE)	P-value for change	Effect estimate (SE)	P-value for group difference
MDS-UPDRS-I
Statin non-users	−0.6 (0.6)	0.32	Reference
Statin users	0.8 (1.0)	0.42	1.5 (1.2)	0.23
Lipophilic statin users	−0.8 (1.2)	0.50	−0.2 (1.4)	0.90
Hydrophilic statin users	4.2 (1.7)	0.018	4.8 (1.8)	0.011
Hydrophilic v. Lipophilic	NA		5.0 (2.1)	0.020
SNC R2*
Statin non-users	1.7 (0.6)	0.008	Reference
Statin users	3.7 (1.1)	0.001	2.0 (1.2)	0.10
Lipophilic statin users	2.8 (1.3)	0.039	1.1 (1.4)	0.44
Hydrophilic statin users	5.3 (1.7)	0.003	3.6 (1.8)	0.050
Hydrophilic v. Lipophilic	NA		2.5 (2.2)	0.25

Data represent estimates on effect of statins on specified outcomes at 18 months while adjusting for age, gender, and disease duration. Non-statin is the reference group unless otherwise stated. Effect estimates represent beta estimates from linear mixed effect model and represent change in addition to that seen in reference group. Values for statin users represent PD subjects taking any statin and are derived from a model considering statin use vs non-statin use. Values for non-statin, lipophilic, and hydrophilic are derived from models considering statin use, use of lipophilic statin, or use of hydrophilic statin. Abbreviations: MDS-UPDRS=Movement Disorders Society Unified Parkinson’s Disease Rating Scale, I=non-motor experiences of daily living.